GlassScriptPhysician profile
Jonathan Q Bui
NPI 1780115964
$1,642.99
in general payments reported to CMS, 2019-2025
23 companies · $567 in 2025
The $567 reported for 2025 was more than what 76% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $116 · 2022: $103 · 2023: $402 · 2024: $454 · 2025: $567.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,423.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,423.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $187.77 | 2023-2025 | Airsupra, Breztri, Farxiga |
| Abbvie INC. | $154.58 | 2022-2025 | Dalvance, Ubrelvy |
| Novo Nordisk INC | $148.46 | 2022-2025 | Wegovy, Ozempic, Rybelsus |
| Pfizer INC. | $140.77 | 2023-2025 | |
| Janssen Pharmaceuticals, INC | $140.34 | 2021-2024 | Xarelto |
| E.R. Squibb & Sons, L.L.C. | $118.18 | 2022-2024 | Eliquis, Camzyos |
| Phathom Pharmaceuticals, INC. | $116.11 | 2024-2025 | Voquezna |
| Boehringer Ingelheim Pharmaceuticals, INC. | $108.92 | 2021-2025 | Jardiance |
| Axsome Therapeutics, INC. | $95.25 | 2025 | Auvelity |
| Lilly USA, LLC | $61.15 | 2023-2025 | Mounjaro, Jardiance, Zepbound |
| Novartis Pharmaceuticals Corporation | $59.30 | 2022-2023 | |
| Genzyme Corporation | $42.36 | 2025 | |
| Amgen INC. | $42.35 | 2024-2025 | Evenity, Repatha, Otezla |
| Vertex Pharmaceuticals Incorporated | $34.19 | 2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $29.34 | 2023-2025 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Idorsia Pharmaceuticals US INC | $29.09 | 2023-2024 | Quviviq |
| Sanofi Pasteur INC. | $26.62 | 2023 | |
| Glaxosmithkline, LLC. | $23.48 | 2023 | Arexvy |
| Merck Sharp & Dohme LLC | $19.28 | 2022 | |
| Exact Sciences Corporation | $18.88 | 2025 | The Cologuard Plus Collection Kit |
| Xeris Pharmaceuticals, INC. | $17.43 | 2023 | Keveyis |
| Teva Pharmaceuticals USA, INC. | $16.28 | 2024 | Ajovy |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $12.86 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Bui listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.